A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFECT OF AZD0780 ON LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA

Registry ID

D7960C00013

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ASTRAZENECA CANADA INC

Start date

2025-06-10

Last update

2025-05-16

Conditions

• HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

Related clinical trials

• OPEN-LABEL, PHASE LB, SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY OF VERVE-102 ADMINISTERED TO PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR PREMATURE CORONARY ARTERY DISEASE WHO REQUIRE ADDITIONAL LOWERING OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL
• AN 8-WEEK OPEN-LABEL, SEQUENTIAL, REPEATED DOSE-FINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AIIROCUMAB IN CHILDREN AND ADOLESCENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA FOLLOWED BY AN EXTENSION PHASE
• DOUBLE-BLIND, RANDOMIZED, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO CHARACTERIZE THE EFFICACY, SAFETY AND TOLERABLITY OF 24 WEEKS OF EVOLOCUMAB FOR LOW DENSITY LIPOPROTEIN-CHOLESTEROL (LSL-C) REDUCTION, AS ADD-ON TO DIET AND LIPID-LOWERING THERAPY, IN PEDIATRIC SUBJECTS 10 TO 17 YEARS OF AGE WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, CROSS-OVER STUDY OF ROSUVASTATIN IN CHILDREN AND ADOLESCENTS (AGED 6 TO <18 YEARS) WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
• A 52 WEEK, PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

View on source registry